A detailed history of Jacobs Levy Equity Management, Inc transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 650,779 shares of IONS stock, worth $22.1 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
650,779
Previous 572,870 13.6%
Holding current value
$22.1 Million
Previous $27.3 Million 4.51%
% of portfolio
0.11%
Previous 0.12%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.06 - $51.86 $3.12 Million - $4.04 Million
77,909 Added 13.6%
650,779 $26.1 Million
Q2 2024

Aug 14, 2024

BUY
$36.45 - $47.7 $40,350 - $52,803
1,107 Added 0.19%
572,870 $27.3 Million
Q1 2024

May 15, 2024

BUY
$42.03 - $53.55 $2.62 Million - $3.33 Million
62,230 Added 12.21%
571,763 $24.8 Million
Q4 2023

Feb 14, 2024

BUY
$43.39 - $51.63 $5.92 Million - $7.04 Million
136,416 Added 36.56%
509,533 $25.8 Million
Q3 2023

Nov 16, 2023

SELL
$38.5 - $47.13 $6.79 Million - $8.32 Million
-176,441 Reduced 32.11%
373,117 $16.9 Million
Q2 2023

Aug 14, 2023

BUY
$34.73 - $43.33 $446,975 - $557,657
12,870 Added 2.4%
549,558 $22.5 Million
Q1 2023

May 15, 2023

SELL
$33.58 - $41.2 $5.14 Million - $6.3 Million
-153,033 Reduced 22.19%
536,688 $19.2 Million
Q4 2022

Feb 14, 2023

BUY
$37.12 - $46.52 $6.6 Million - $8.27 Million
177,746 Added 34.72%
689,721 $26.1 Million
Q3 2022

Nov 15, 2022

SELL
$36.54 - $48.66 $3.83 Million - $5.1 Million
-104,791 Reduced 16.99%
511,975 $22.6 Million
Q2 2022

Aug 15, 2022

SELL
$31.71 - $43.0 $31.8 Million - $43.1 Million
-1,001,501 Reduced 61.89%
616,766 $22.8 Million
Q1 2022

May 16, 2022

BUY
$29.88 - $37.04 $6.3 Million - $7.81 Million
210,879 Added 14.98%
1,618,267 $59.9 Million
Q4 2021

Feb 14, 2022

BUY
$25.61 - $35.1 $5.54 Million - $7.59 Million
216,152 Added 18.15%
1,407,388 $42.8 Million
Q3 2021

Nov 15, 2021

BUY
$33.54 - $40.55 $3.58 Million - $4.33 Million
106,814 Added 9.85%
1,191,236 $40 Million
Q2 2021

Aug 16, 2021

BUY
$34.54 - $47.25 $31.8 Million - $43.5 Million
921,476 Added 565.51%
1,084,422 $43.3 Million
Q1 2021

May 17, 2021

SELL
$42.51 - $63.78 $1.75 Million - $2.63 Million
-41,235 Reduced 20.2%
162,946 $7.33 Million
Q4 2020

Feb 16, 2021

BUY
$45.3 - $60.27 $2.48 Million - $3.3 Million
54,709 Added 36.6%
204,181 $11.5 Million
Q3 2020

Nov 16, 2020

SELL
$47.45 - $62.95 $380,881 - $505,299
-8,027 Reduced 5.1%
149,472 $7.09 Million
Q2 2020

Aug 17, 2020

BUY
$46.85 - $61.05 $2.43 Million - $3.17 Million
51,922 Added 49.18%
157,499 $9.29 Million
Q1 2020

May 15, 2020

BUY
$41.6 - $63.4 $867,484 - $1.32 Million
20,853 Added 24.61%
105,577 $4.99 Million
Q4 2019

Feb 14, 2020

SELL
$53.85 - $65.27 $3.88 Million - $4.71 Million
-72,116 Reduced 45.98%
84,724 $5.12 Million
Q3 2019

Nov 14, 2019

BUY
$59.06 - $72.15 $2.64 Million - $3.23 Million
44,770 Added 39.95%
156,840 $9.4 Million
Q2 2019

Aug 13, 2019

BUY
$62.09 - $86.14 $3.69 Million - $5.11 Million
59,380 Added 112.7%
112,070 $7.2 Million
Q1 2019

May 14, 2019

BUY
$52.92 - $81.17 $2.79 Million - $4.28 Million
52,690 New
52,690 $4.28 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $4.83B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.